In a recent transaction, Jennifer L. Good, the President and CEO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), sold 25,037 shares of the company's common stock, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $2.8588, totaling approximately $71,575.
The sales took place in multiple transactions with prices ranging from $2.82 to $2.955. The exact number of shares sold at each price point within this range can be provided upon request, as noted in the filing's footnotes.
On the same day, Good also exercised options to acquire 25,037 shares of Trevi Therapeutics common stock at a price of $2.19 per share, amounting to a total transaction value of $54,831. It is noteworthy that these options were part of a grant from July 2, 2014, which vested in stages between June 11, 2015, and June 11, 2018.
Following these transactions, Good holds a total of 213,313 shares directly. These moves are part of her regular financial planning and portfolio management.
Investors often monitor insider transactions as they provide insights into executives' confidence in the company's performance and outlook. However, such transactions can occur for various reasons, and the context provided by the company and its executives can offer additional understanding of these moves.
InvestingPro Insights
Amidst the recent insider transactions by Jennifer L. Good, President and CEO of Trevi Therapeutics, Inc. (NASDAQ:TRVI), investors may find the following InvestingPro Insights particularly informative:
Trevi Therapeutics currently holds a market capitalization of $186.65 million, reflecting its size and scale in the pharmaceutical industry. Despite a challenging period, the company has seen a large price uptick over the last six months, with a 139.47% increase, signaling a significant shift in investor sentiment.
The company's financial health shows some contrasting metrics. An InvestingPro Tip highlights that Trevi Therapeutics holds more cash than debt on its balance sheet, which could be seen as a positive sign of financial stability. Additionally, the company has liquid assets that exceed its short-term obligations, providing some reassurance about its ability to meet immediate financial needs.
However, there are concerns as well. Trevi Therapeutics is quickly burning through its cash and has been noted for weak gross profit margins. Furthermore, analysts have revised their earnings downwards for the upcoming period, and they do not anticipate the company will be profitable this year. These concerns are reflected in a negative P/E ratio for the last twelve months as of Q1 2024, standing at -5.58.
For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available that delve deeper into Trevi Therapeutics' financials and projections. For instance, the company's net income is expected to drop this year, and it has not been profitable over the last twelve months. Moreover, the company does not pay a dividend to shareholders, which might be a consideration for income-focused investors.
To explore these insights further and access a total of 10 InvestingPro Tips for Trevi Therapeutics, investors can visit https://www.investing.com/pro/TRVI. Those interested in a subscription can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.